10 citations
,
December 2020 in “Experimental and Molecular Pathology” miR-133b promotes hair growth and could be a potential treatment for hair loss.
21 citations
,
July 2006 in “Veterinary dermatology” CD34 marks potential stem cells in dog hair follicles.
21 citations
,
April 2008 in “Toxicologic Pathology” CI-1033 causes skin lesions in rats, similar to humans, due to EGF receptor inhibition.
10 citations
,
July 2013 in “British Journal of Dermatology” High MUC-18/MCAM levels in blood indicate a worse outlook for melanoma patients.
3 citations
,
December 2023 in “Aging” hsa_circ_0002980 can help stop liver cancer cells from growing and spreading.
41 citations
,
April 2019 in “PLOS genetics” CD34+ and CD34- melanocyte stem cells have different regenerative abilities.
6 citations
,
March 2018 in “The American journal of dermatopathology/American journal of dermatopathology” BerEP4 and CD34 staining can help tell apart tricholemmoma from basal cell carcinoma.
November 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” DAB labeling effectively identifies collagen type III and PDGFR in horse skin, but may show false positives.
January 2026 in “Medicina” CD34 is absent in most basal cell carcinoma cells but present in surrounding skin.
11 citations
,
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” A specific group of skin stem cells was found to help maintain hair follicle cells.
January 2026 in “Journal of Dermatological Science” DcR3 helps heal wounds and regrow hair by changing macrophages to a repair-focused type.
April 2010 in “Cancer Research” Basal cell carcinomas may use IDO to protect themselves from the immune system.
April 2026 in “Frontiers in Cell and Developmental Biology” CD200- cells in hair follicles have a higher ability to regenerate hair.
32 citations
,
January 2012 in “Clinical & Developmental Immunology” Targeting CD200 could be a new treatment for rheumatoid arthritis.
September 2025 in “Experimental & Molecular Medicine” Small molecules KY19382 and KY19334 may help treat skin cancer by reducing CDK1 levels and blocking harmful cell signals.
17 citations
,
January 2010 in “PubMed” CD10 helps distinguish between basal cell carcinoma and benign hair follicle tumors.
37 citations
,
February 2007 in “Experimental Dermatology” Increasing PDCD4 protein may help prevent or treat some skin cancers.
14 citations
,
March 2015 in “Stem Cell Research & Therapy” ABCG2 protein marks stem-like skin cells in human epidermis.
May 2024 in “International journal of medicine and psychology.” Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.
4 citations
,
January 2018 in “Microscopy research” Scientists found markers called CD34 and CD200 that help identify stem cells in mouse and human hair follicles.
April 2018 in “Journal of Investigative Dermatology” CREB, a protein that can promote cancer traits, is controlled by β-catenin in skin cancer cells.
1 citations
,
May 2019 in “Cytotherapy” The new ddPCR method reliably detects unwanted viruses in CAR-T cell products, ensuring their safety for patients.
36 citations
,
March 2011 in “Stem Cell Reviews and Reports” April 2012 in “Cancer Research” Stat3 influences keratinocyte stem cell behavior, affecting differentiation and migration.
January 2025 in “Cell Communication and Signaling” CXXC5 can both suppress and promote cancer, making it a complex target for treatment.
10 citations
,
December 2015 in “International Journal of Dermatology” CK 15, follistatin, and Bmi-1 can help differentiate basal cell carcinoma from squamous cell carcinoma.
January 2026 in “Therapeutics” SCUBE3 is a potential target for cancer and alopecia treatment but is challenging to target due to its varied roles.
November 2022 in “Journal of Investigative Dermatology” ILC1-like cells can cause alopecia areata by themselves.
141 citations
,
May 2007 in “Cancer Research” CD34 is crucial for skin tumor development in mice.
1 citations
,
November 2024 in “Cureus” Recognizing RSCC is crucial due to its aggressive nature and high risk of poor outcomes.